Latest News

Weekly News Roundup | 9 November 2026

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

read more

Latest News

Online Prescribing Is Moving Faster Than Regulation

Online Prescribing Is Moving Faster Than Regulation

Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...

read more
Clinical Trials Roundup | 25 September 2026

Clinical Trials Roundup | 25 September 2026

The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...

read more
Rethinking the Office: The Need for Healthier Buildings

Rethinking the Office: The Need for Healthier Buildings

For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Clinical Trials Roundup | 8 May 2026

Clinical Trials Roundup | 8 May 2026

Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...

read more
GSK Secures $1bn Rights to SiranBio siRNA Therapy

GSK Secures $1bn Rights to SiranBio siRNA Therapy

GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...

read more
Paediatric Trials: Why Children Remain Therapeutic Orphans

Paediatric Trials: Why Children Remain Therapeutic Orphans

Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...

read more
Global Nursing Shortage: The Life Sciences Risk

Global Nursing Shortage: The Life Sciences Risk

For the life sciences sector, the global nursing shortage is not a background public health concern. It is a clinical trial staffing problem, a pharmaceutical market access problem, and a real-world evidence problem. The WHO's 2025 State of the World's Nursing report...

read more
Why Clinical Trial Diversity Remains a Problem

Why Clinical Trial Diversity Remains a Problem

For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...

read more
Weekly News Roundup | 4 May 2026

Weekly News Roundup | 4 May 2026

Life science news 4 May 2026: Eli Lilly's record $19.8 billion quarterly earnings, the FDA's real-time clinical trial revolution and a landmark week for UK regulatory reform define a momentous seven days for global life science. Eli Lilly reported worldwide revenue of...

read more
The Gap Between Precision Medicine and Clinical Reality

The Gap Between Precision Medicine and Clinical Reality

Precision medicine is no longer a futuristic concept. Genomic panels, pharmacogenomic testing, advanced biomarker analysis, and individualized risk stratification tools are all available today. Yet for the vast majority of patients walking into a primary care office,...

read more
Clinical Trials Roundup | 1 May 2026

Clinical Trials Roundup | 1 May 2026

Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...

read more
Longevity Biotech: Separating the Science from the Hype

Longevity Biotech: Separating the Science from the Hype

The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...

read more
Clinical Trials Roundup | 8 May 2026

Clinical Trials Roundup | 8 May 2026

Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...

read more
GSK Secures $1bn Rights to SiranBio siRNA Therapy

GSK Secures $1bn Rights to SiranBio siRNA Therapy

GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...

read more
Paediatric Trials: Why Children Remain Therapeutic Orphans

Paediatric Trials: Why Children Remain Therapeutic Orphans

Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...

read more
Global Nursing Shortage: The Life Sciences Risk

Global Nursing Shortage: The Life Sciences Risk

For the life sciences sector, the global nursing shortage is not a background public health concern. It is a clinical trial staffing problem, a pharmaceutical market access problem, and a real-world evidence problem. The WHO's 2025 State of the World's Nursing report...

read more
Why Clinical Trial Diversity Remains a Problem

Why Clinical Trial Diversity Remains a Problem

For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...

read more
Weekly News Roundup | 4 May 2026

Weekly News Roundup | 4 May 2026

Life science news 4 May 2026: Eli Lilly's record $19.8 billion quarterly earnings, the FDA's real-time clinical trial revolution and a landmark week for UK regulatory reform define a momentous seven days for global life science. Eli Lilly reported worldwide revenue of...

read more
The Gap Between Precision Medicine and Clinical Reality

The Gap Between Precision Medicine and Clinical Reality

Precision medicine is no longer a futuristic concept. Genomic panels, pharmacogenomic testing, advanced biomarker analysis, and individualized risk stratification tools are all available today. Yet for the vast majority of patients walking into a primary care office,...

read more
Clinical Trials Roundup | 1 May 2026

Clinical Trials Roundup | 1 May 2026

Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...

read more
Longevity Biotech: Separating the Science from the Hype

Longevity Biotech: Separating the Science from the Hype

The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Report Finds Seven in Ten Leaders Bullied by Their Teams

Report Finds Seven in Ten Leaders Bullied by Their Teams

Healthcare organisations invest significantly in psychosocial risk frameworks, governance structures and leadership development. Yet a new international study highlights a type of organisational risk that most of those frameworks are not designed to detect. It is a...

read more
Trump FDA Drug Approvals: Global Impact

Trump FDA Drug Approvals: Global Impact

Trump FDA Drug Approvals: How US Regulatory Upheaval Is Reshaping the Global Pharmaceutical Industry The United States Food and Drug Administration has long been regarded as the gold standard of drug regulation. When a medicine receives FDA approval, it carries a...

read more
Most Supplement Companies Skip the RCT

Most Supplement Companies Skip the RCT

Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...

read more
Physiology: The Missing Layer in Precision Medicine

Physiology: The Missing Layer in Precision Medicine

Precision medicine has been positioned as one of the most promising evolutions in modern healthcare. Gene panels. Liquid biopsies. Microbiome-targeted therapies. Multi-omics integration. The premise is compelling: the more precisely we can characterize biological...

read more
Weekly News Roundup | 27 April 2026

Weekly News Roundup | 27 April 2026

Life science news 27 April 2026: Eli Lilly's $7 billion in vivo CAR-T deal, Trump's psychedelics executive order and a first-ever gene therapy for hearing loss headline a landmark week across global life science. Eli Lilly announced on 20 April its acquisition of...

read more
Life Science Daily News: Join the Community

Life Science Daily News: Join the Community

A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...

read more

Further News

Why Ingredient Research Is Only the Beginning of a Health Product

I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...

Weekly News Roundup | 24 August 2026

Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...

The Role of Ambient AI in the Future of Specialty Care

For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...

Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics

Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...

APAC Biopharma in 2026: Asia’s Shift From Supplier to Source

APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...

Beyond the Benchmark: A Four-Layer Framework for Evaluating Healthcare AI

Healthcare AI is often evaluated where it is easiest to measure: on a dataset. Accuracy, sensitivity, specificity, calibration, retrieval quality, hallucination rates and task-completion scores all matter. But they answer only the first question: can the model perform...

The Next Era of Cardiorenal Care Is Precision Fluid Management

Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...

Clinical Trials Roundup | 21 Aug 2026

Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...

The Ketogenic Diet: Why Long-Term Safety Deserves Greater Scrutiny

The ketogenic diet has transitioned from a highly specialized therapeutic intervention to a widely promoted dietary strategy for weight loss, metabolic health, inflammation, and, in some circles, cancer prevention or treatment. Its popularity has outpaced the strength...

Human-in-the-Loop or Human-on-the-Loop? Pharma’s AI Authority Test

“But what can this AI model actually do?” It’s a common question being asked across the life sciences industry. Can it classify a symptom, summarize a trial record, predict a molecule’s behavior, or monitor a manufacturing process? Those capabilities matter, but they...

Physical Activity and Dementia: The Evidence Base Is Uneven

The link between physical activity and dementia depends on where that activity happens, according to a meta analysis of 74 studies covering more than four million adults. Leisure time exercise was associated with a lower risk of dementia, while activity undertaken at...

The Next Recruitment Challenge Isn’t Awareness, It’s Qualification

For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.